The cell-based assays market size is estimated to be USD 15,984.1 million in 2022 and is expected to witness a CAGR of 8.87% during the forecast period 2023-2033. Rising need for drug discovery, the increasing requirement for biotechnology research, and the growing incidences of infectious diseases, cancer, autoimmune diseases, and genetic disorders are factors contributing to the market growth. Furthermore, increasing customised tests by private companies to meet research requirements and growing advancements in drug discovery is expected to propel the market. However, high instrument prices and reagent constraints is expected to hinder the growth.

Private companies provide customized tests to meet unique research requirements, with an emphasis on a specific therapeutic plan to treat a certain disease. For instance, Menarini Silicon Biosystems introduced CELLSEARCH in November 2021, a test created in a lab to help count multiple myeloma cells using a blood sample. Also, it makes it easier for physicians to identify people at high risk.

Growing advancements in drug discovery is predicted to drive the market growth. A favourable environment for industrial expansion is projected to be provided by the growing advancements in drug discovery. For instance, Proxidrugs, a potential therapeutic alternative for infections, cancer, and Alzheimer’s disease, was developed by researchers at the Fraunhofer Institute in September 2022. It uses a cells-based waste disposal system.

Segmentation

By Product & Service

The market is categorized into assay kits, reagents, probes & labels, cell lines, microplates, and instruments. In 2022, the assay kits accounted for the highest revenue share due to its effectiveness in a variety of biopharmaceutical applications. These specific test kits have a great demand since they significantly reduce ambiguity by providing accurate diagnostic results. Additionally, the segment is driven by its comprehensive strategy, which includes providing all the assay’s consumables. For instance, the KeratinoSens (keratinocyte cell lines) produce the luciferase reporter gene when the instaCELL Skin Sensitization Assay Kit (by Accelerate) recognises early essential events of the skin sensitization process.

By Application

The market is categorized into drug discovery, basic research, and others. In the global market, the drug discovery segment accounted for the largest revenue share in 2022 owing to rising demand for novel therapeutic drugs to treat a wide range of diseases. A surge in therapeutic drug discovery research efforts and increased market competitiveness for FDA approvals are driving the expansion of the drug discovery market. The basic research application is anticipated to show significant industry share throughout the course of the projection period. Cell-based assays serve as the foundation of life sciences research and help us better comprehend a variety of biological activities in health and disease.

By End User

The market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2022, the pharmaceutical & biotechnology companies segment accounted for the largest revenue share owing to the fact that cell-based assays are useful for determining the external stimuli or pharmacological substances affect cellular activity in general in the pharmaceutical industry. In addition, cell-based drug screening assays have been extensively used in drug development research to select promising lead molecule candidates from hundreds of chemical compound libraries. Such extensive uses of cell-based tests in the pharmaceutical sector fuel segment expansion.

Regional Markets

In 2022, North America region accounted for the highest revenue in the cell-based assays market and is expected to maintain its dominance during the forecast period. This is attributed to the extensive research conducted in several research institutes financed jointly by academic research institutes and pharmaceutical industry giants around the region. For instance, in April 2022, Labcorp and Xcell Biosciences, Inc., signed a collaboration agreement for the advancement of crucial laboratory work aimed at increasing the safety and efficacy of Cell & Gene Therapies (CGTs), to help in the commercialization of novel CGTs. The growth of the regional market is anticipated to be significantly influenced by the rising demand for novel therapeutic medicines in Asia Pacific. Another factor propelling the growth of the regions is the rapid construction of the infrastructure and rising government investment in R&D. The region’s largest pharmaceutical companies fund several research initiatives, which has expanded demand for cell-based assays across a range of applications.

Competitor Insights

Some of the key players operating in the cell-based assays market are BD, CorningInc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corp., Charles River Laboratories, Lonza, Promega Corp., and F. Hoffmann-La Roche Ltd.

Major players in the industry are focusing on strategic partnerships, strategic alliances, and regional expansions in developing and profitable regions.

• For instance, Promega Corp. and Fujifilm Cellular Dynamics, Inc. announced a collaboration agreement in March 2022 for the development of a novel assay programme for use in drug discovery. The goal of the partnership is to develop novel assays for the process of drug discovery by combining a wide range of specially differentiated cells with Promega’s biosensor and intracellular bioluminescence.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product & service, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Cell-based Assays Market Report 2022 – 2033

Product & Service (Revenue, USD Million), 2022 – 2033

• Assay Kits
• Reagents
• Probes & Labels
• Cell Lines
• Microplates
• Instruments

Application (Revenue, USD Million), 2022 – 2033

• Drug Discovery
• Basic Research
• Others

End user (Revenue, USD Million), 2022 – 2033

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA